Sponsored by
Latest
Topics
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Featured
Strategy
Strategic Acquisitions: Their Mistake Could Be Your Next Opportunity
During this interest rate and inflation cycle, make your M&A shopping list early but be selective.
By
Kal Vadasz
| June 27, 2022
Read More
Resources
CFO Live
Sign Up
Menu
Topics
Accounting & Tax
Corporate Finance
Human Capital
Risk & Compliance
Strategy
Technology
Explore
Search
Latest
Resources
CFO Live
Sign Up
Sponsored by
Actelion
Financial Performance
J&J Posts $17.7B in Revenue, Misses Estimates
Tepid growth in pharmaceuticals and consumer products held back first-quarter sales but the company is still confident it will meet its full-year guidance.
By
Matthew Heller
| April 19, 2017
Read More
Strategy
J&J Boosts Drug Roster With $30B Actelion Deal
The largest acquisition in J&J's history gives it access to Actelion's portfolio of high-margin treatments for rare diseases.
By
Matthew Heller
| January 26, 2017
Read More